Switching to biosimilars in dermatology: a patients’ perspective

Abstract

Biosimilars are legitimate copies of a biopharmaceuticals (originator biologics) that are no longer protected by patent and have undergone rigorous analytical and clinical assessment compared with their reference product, demonstrating efficacy and safety with significant cost savings when prescribed. This qualitative study was conducted to better understand the patient experience around the transition to biosimilars. Three main themes that influenced patient decisions were identified: the impact of disease, the information around biosimilars and patient autonomy. This study highlights the importance of counselling patients appropriately regarding transitioning to biosimilars and reinforces the importance of good communication to ensure patient empowerment and satisfaction.